OXFORD, UK, April 28, 2026

Scancell Holdings plc, a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, has reported significant progress across its pipeline, reinforcing its position in the development of next-generation immuno-oncology treatments. The company’s update highlights advancements in its ModiFY® and ImmunoBody® platforms, which are designed to harness and enhance the body’s immune response to target and eliminate cancer cells

This progress comes at a time when immunotherapy continues to transform the oncology landscape, offering new hope for patients with difficult-to-treat cancers. Scancell’s differentiated approach focuses on activating potent and durable T-cell responses, positioning its therapies as promising candidates in both monotherapy and combination treatment settings.

Pipeline Progress Driven by Innovative Platforms

Scancell’s proprietary ModiFY® platform targets post-translational modifications of tumor-associated antigens, enabling the immune system to recognize and attack cancer cells that would otherwise evade detection. Its lead candidate, Modi-1, is currently being evaluated in clinical studies for solid tumors, including ovarian and head and neck cancers.

In parallel, the company’s ImmunoBody® platform is advancing DNA-based cancer vaccines, such as SCIB1/iSCIB1+, which are designed to generate high-avidity T-cell responses against melanoma-associated antigens. Early clinical data have demonstrated encouraging immune activation and safety profiles, supporting continued development in combination with checkpoint inhibitors.

Advertisement

cGxPJobs Banner

These platform technologies represent a novel approach to cancer treatment, aiming to overcome immune tolerance and deliver strong, targeted anti-tumor responses. The ability to combine these therapies with existing immuno-oncology agents further enhances their potential clinical impact.

Clinical Strategy Focuses on Combination Therapies

A key element of Scancell’s strategy is the integration of its immunotherapies with established treatments, particularly checkpoint inhibitors, to improve response rates and durability. Combination approaches are increasingly recognized as essential in oncology, where single-agent therapies often face resistance mechanisms.

Scancell is actively exploring combinations that could amplify immune responses and enhance tumor eradication, particularly in patients with advanced or refractory cancers. The company’s clinical programs are designed to generate robust data supporting both safety and efficacy, paving the way for potential late-stage trials and regulatory engagement.

This focus on combination therapy aligns with broader industry trends, where synergistic treatment strategies are becoming the standard for achieving meaningful clinical outcomes in complex cancers.

Positioning for Growth in Immuno-Oncology Innovation

Scancell’s ongoing progress reflects its commitment to addressing significant unmet needs in oncology, particularly in cancers with limited treatment options. The company’s pipeline is supported by a strong scientific foundation and a diversified approach to immunotherapy development, enabling it to target multiple cancer types and patient populations.

With immuno-oncology representing one of the fastest-growing segments in biopharmaceutical research, Scancell is well-positioned to capitalize on emerging opportunities, supported by its innovative platforms and expanding clinical data. The company continues to engage with partners, regulators, and the broader scientific community to advance its programs toward commercialization.

As clinical development progresses, Scancell’s therapies have the potential to redefine cancer treatment paradigms, offering more effective, targeted, and durable solutions for patients worldwide. The company’s strategic focus on innovation, combination therapies, and immune system activation underscores its role as a key contributor to the future of oncology care.

Source: Scancell press release